Please login to the form below

I have forgotten my password

AZD3293

This page shows the latest AZD3293 news and features for those working in and with pharma, biotech and healthcare.

Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat

Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat

The demise of the BACE1 inhibitor – also known as AZD3293/LY3314814 – adds to the litany of failures among drugs intended to treat Alzheimer’s, and specifically those trying to slow down

Latest news

Biogen rises on more positive data for Alzheimer's candidate

compounds. . Last week, it partnered with AstraZeneca (AZ) on MEDI1814, an antibody against amyloid-beta 42 (Aβ42) in phase I trials, and is also working with AZ on BACE inhibitor AZD3293,
Lilly taps AstraZeneca for another anti-amyloid drug

The two companies are already working together on AZD3293, a BACE inhibitor which is designed to interrupt the formation of Aβ at an early stage in the process, and are running
Lilly sinks as solanezumab fails again in Alzheimer's

AZD3293. Ricks has previously suggested that if EXPEDITION3 was a bust then the expensive, 2, 500-patient prodromal trial will probably be abandoned.
AZ-Lilly start second pivotal trial of fast-tracked Alzheimer's drug

AMARANTH could be first treatment to target underlying mechanism. . AstraZeneca and Eli Lilly's collaboration in Alzheimer's disease continues to make progress, as their AZD3293 drug is granted a ... AZ and Lilly are already carrying out one phase
Eisai and Biogen plan phase III trials for Alzheimer's drug

others. Merck has already started phase III trials of its MK-8931 candidate, while Lilly and AZ recently did likewise with AZD3293.

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest Intelligence

Deal Watch October 2016

Lilly. AZD3293. $500 profit share. Neurology 2012. Impax US. Zomig US.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Director: Competitive Salary Offered

Account Director – Health Policy – Global Agency: Salary TBC

Medical Writer: Salary TBC

Business Director: Competitive Salary Offered

Senior Director – Healthcare PR – Global Agency: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Senior Account Manager: Competitive Salary Offered

Account Manager / Account Director: Competative

Account Director, Medical Education: Salary TBC

Client Services Director – Medical Education Agency – North West...: Salary TBC

Account Director – Healthcare Marketing – Berks: Salary TBC

Senior Account Director development role to Business Director, H...: Excellent package

Account Manager / Senior Account Manager: 35, 000-40, 000

Senior Medical Writer: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Associate Director: £75, 000-90, 000

Global Business Development Director – Health Education: excellent commission

Subscribe to our email news alerts

PMHub

Add my company

Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt: ...
The UK’s new five-year pricing agreement: Pharma has agreed to capped growth again – in exchange for uptake promises...
Digital applications are transforming the market access landscape: Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Quick links

Infographics

Multimedia

<>